Bellion Spirits, a New York and New Jersey-based company, is striving to revolutionize the alcohol industry by supposedly minimizing the health risks associated with consuming alcohol. By infusing their products with patented NTX Technology, Bellion Spirits claims to have produced alcoholic beverages that lessen the burden of alcohol on the body.
NTX Technology is an all-natural, precise blend of glycyrrhizin acid, D-mannitol, and potassium sorbate that was developed by Chigurupati Technologies in India. Human and animal studies conducted by Chigurapati Technologies supposedly demonstrate that when infused with alcoholic beverages, NTX lowers the toxicity of alcohol on the liver and diminishes the damaging effects of free radicals on cellular DNA without affecting the taste or desired effects of alcohol. However, Bellion Spirits is currently unable to promote or advertise these health claims on their products, as the Alcohol and Tobacco Tax and Trade Bureau (TTB), part of the Department of the Treasury, have not granted approval. Bellion Spirits filed a petition with the TTB in April 2016, but the TTB have requested three extensions and have yet to give their final decision.
Bellion’s Spirits flagship product, Bellion Vodka, was introduced last year. In the works to be released this year are two new spirits, Dera Tequila and SMOAK whiskey. Bellion Spirits aims to deliver a total of 16 NTX-infused alcoholic beverages to the market over the next several years, including beer and wine. Bellion Spirits is also currently working on improving NTX Technology, adding more protective properties and benefits.
Alcohol consumption is very much a part of the American culture with more than 50% of American adults consuming alcohol within the last month. Although Bellion Spirits’ NTX-infused alcohol can in no way guard against the significant adverse social and economic burdens of alcohol abuse, it may help limit certain health risks associated with alcohol consumption, if proven effective.